Preliminary Results from the Phase I Part of a First-in-human Phase I/II Study of HH2853, an EZH1/2 Inhibitor, in Patients with Relapsed/refractory Non-Hodgkin Lymphomas or Advanced Solid Tumors
CANCER RESEARCH（2023）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined